NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics With Acute Myocardial Infarction
SANTA CLARA, Calif., April 7, 2011 /PRNewswire/ -- PR Newswire – NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that the Company has been invited by the American Diabetes Association (ADA) to present the results of a key study showing that NewCardio's urgent care solution, my3KG™, had substantially greater accuracy than expert cardiologists' interpretation of standard 12-lead ECG (12L ECG) in diagnosing Acute Myocardial Infarction (AMI) in diabetic patients. The presentation will be made at the 71st Annual ADA Scientific Sessions to be held in San Diego, CA, June 24-28, 2011. In addition, the ADA has selected this presentation to be showcased in the Guided Audio Poster Tour, which features expert moderators that share their perspectives with attendees, highlighting novel and important developments in the field.
Dr. Ihor Gussak, MD, PhD, NewCardio's Chief Medical Officer, commented, "We are delighted to present our study results at this important gathering of diabetes experts, and particularly pleased that the ADA program committee chose to feature our presentation in a moderated poster session. Accurate and timely AMI diagnosis is a matter of great concern for diabetologists, and we believe our results show that my3KG can play a major role in solving it. The moderated poster session provides the opportunity to present our results directly to leading diabetes experts, and have one-on-one interactions that will allow us to discuss and explain the importance of our results in detail."
Study Background and Results
Diabetics with AMI represent a very large and growing patient group, and currently affect over 10% of adults in the U.S. Moreover, the incidence of AMI is two to four times greater in diabetics than in the general population, according to ADA and American Heart Association statistics. Accurate and timely diagnosis of AMI is notorious